scorecardresearch
Clear all
Search

COMPANIES

No Data Found

NEWS

No Data Found
Sign in Subscribe
Biocon subsidiary acquires Pfizer's research facility

Biocon subsidiary acquires Pfizer's research facility

According to Biocon Biologics CEO Christiane Hamacher, the high-end integrated R&D facility in Chennai will enable Biocon Biologics to expand its R&D capability and accelerate its journey towards meeting its strategic long-term goal of addressing the needs of millions of patients worldwide

Biocon has acquired R&D capital assets for a 60,000-square feet research facility at Ticel Bio Park in Chennai Biocon has acquired R&D capital assets for a 60,000-square feet research facility at Ticel Bio Park in Chennai

Indian biotechnology major Biocon on Tuesday said it has acquired a Chennai-based research and development (R&D) facility from Pfizer Healthcare India through its subsidiary Biocon Biologics. The Kiran Mazumdar Shaw-led company, however, did not disclose the financial transaction involved in the deal.

The company has acquired R&D capital assets for a 60,000-square feet research facility at Ticel Bio Park in Chennai, Biocon said in a filing to the Bombay Stock Exchange.

TICEL Bio Park is a hub for the biotech R&D industry in major domains such as medical biotechnology, nutraceuticals, agricultural biotechnology and bioinformatics and provides world class infrastructure support.

"The high-end integrated R&D facility in Chennai will enable Biocon Biologics to expand its R&D capability and accelerate its journey towards meeting its strategic long-term goal of addressing the needs of millions of patients worldwide," Biocon Biologics CEO Christiane Hamacher said.

Hamacher further stated that this investment will allow the company to fast-forward development of its biosimilars from lab to pilot scale.

Also Read: BT Buzz: Healthy Q1 results but challenges galore for Indian pharma

"The facility will house an early stage research and innovation center including a pilot scale R&D unit, well-equipped with cell line development, drug substance process development from bench scale to 400 litre scale bioreactors, drug product formulation laboratories and analytical R&D laboratories,"  the company said in the regulatory filing.

The facility is expected to be operational in a few months post qualification and will house over 250 scientists who will have access to state of the art R&D labs equipped with over 500 high-end process and analytical instrumentation.

Currently, Biocon Biologics has a 200,000 sq. ft of the research & development centre at Biocon Park, Bengaluru, India. The company has a product pipeline of 28 molecules, including 11 with Mylan, few with Sandoz and rest on its own.

Edited by Chitranjan Kumar

Also Read: Reliance Jio-owned Haptik acquires conversational commerce platform Buzzo.ai

Published on: Sep 24, 2019, 7:36 PM IST
×
Advertisement